News

Thursday
Jan052017

MinervaX announces positive data from Phase I clinical trial

MinervaX announces positive results from Phase I trial in 240 healthy adult women with its innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns.

Press release
Monday
Sep192016

Innovation Foundation Grant

MinervaX announces that the company has been awarded a grant worth DKK 4.1 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for the development of its Group B Streptococcal Vaccine. 

Wednesday
Aug312016

Primary Endpoint Data from Phase I Part B

MinervaX announces that it today data have been received from the primary 3-month time point clinical endpoint of the Phase I Part B. The data supports dose-selection made based on Part A. The data further supports the vaccine is highly immunogenic already 14 days after the first dose, and that the antibodies are functionally active in killing Group B Streptococcus and preventing host-invasion.

Tuesday
Apr052016

Completion of enrolment of Phase I Part B

MinervaX announces that it today has enrolled and dosed the last of 240 subjects in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN.

Monday
Feb152016

Equity Financing

MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an equity financing led by Novo Seeds, the seed arm of Novo A/S, supported by Sunstone Capital and LF Investment.